ClinicalTrials.gg
RecruitingNCT06669247COSTIMMUpdated Aug 5, 2026

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

A Phase 1/2 interventional study of Linvoseltamab and REGN7945+Linvoseltamab in Relapsed/Refractory Multiple Myeloma, sponsored by Regeneron Pharmaceuticals. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
186
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing linvoseltamab in Multiple Myeloma — 13 open to participants now, 15 under way, 4 of them phase 3. linvoseltamab · Multiple Myeloma.

Planned enrollment
8th of 16
186 · median 168
Started
2024
with 3 others
Phase 1/2
5 of 16
4 open now
Primary completion
2033-11
later than 11 of 14 live
Registered
7th of 16
by date
Lead sponsor
10 of 16
Regeneron Pharmaceuticals

Among the 16 studies testing linvoseltamab in Multiple Myeloma, this one is the 8th largest by planned enrollment, is one of 4 that started in 2024, is one of 5 in phase 1/2, reaches primary completion later than 11 of the 14 other live ones, and was the 7th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

13 of the 16 studies testing linvoseltamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About linvoseltamab

linvoseltamab: first FDA approval 2025 (LYNOZYFIC), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing linvoseltamab in Multiple Myeloma, or all of them as a file.
02

Study summary

This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined).

This study is the first time REGN7945 will be tested in humans. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after several other therapies had failed.

The aim of the study is to see how safe, tolerable, and effective REGN7945 is when given in combination with linvoseltamab, compared with linvoseltamab alone.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug(s)
  • How many people treated with REGN7945 and linvoseltamab compared to linvoseltamab alone have improvement of their multiple myeloma and by how much
  • How long people benefit from receiving REGN7945 in combination with linvoseltamab compared with linvoseltamab alone
  • How much study drug(s) is in the blood at different times
  • Whether the body makes antibodies against the study drugs(s) (which could make the study drug(s) less effective or could lead to side effects)
  • If there is any change in pain and cancer-related symptoms, how well people are able to function, and their quality of life when taking the study drug(s)
03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

Keywords

  • R/RMM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. (ECOG) performance status ≤1 as described in the protocol
  2. Received at least 3 including exposure to at least 1 anti-CD38 antibody, 1 immunomodulatory imide drug (IMiD), and 1 proteasome inhibitor (PI) and have demonstrated disease progression on or after the last therapy, as defined in the protocol. Prior treatment with other BCMA directed immunotherapies, including BCMA CAR-T cells and BCMA antibody-drug conjugates (Phase 1 and 2), and with BCMA x CD3 bispecific antibodies (Phase 1 only), is allowed
  3. Participants must have the for response assessment as described in the protocol
  4. Adequate hematologic, hepatic, and renal function as described in the protocol

Key Exclusion Criteria:

  1. Diagnosis of plasma cell leukemia, primary systemic light-chain amyloidosis (including myeloma associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  2. Treatment with any systemic anti-cancer therapy within 5 half-lives or within 28 days before first administration of study drug, whichever is shorter
  3. History of stem cell transplantation within 6 months, or autologous stem cell transplantation within 12 weeks of the start of study treatment
  4. Treatment with systemic treatment with more than 10 mg per day of prednisone or steroid equivalent within 72 hours of start of study drug
  5. Participants who have known central nervous system (CNS) involvement with MM or known or suspected progressive multifocal leukoencephalopathy (PML), history of a neurocognitive condition or CNS disorder, or history of seizure within 12 months prior to study enrollment
  6. Live or within 28 days before first study drug administration with a vector that has replicative potential
  7. Has received a COVID-19 vaccination within 1 week of planned start of study medication as described in the protocol
  8. Myelodysplastic syndrome or another in the past 3 years, except for nonmelanoma skin cancer, in situ carcinoma, thyroid cancer, or low-risk early stage prostate adenocarcinoma, as described in the protocol
  9. Significant cardiovascular disease as described in the protocol
  10. Uncontrolled infection with , Hep B or Hep C infection, or other uncontrolled infection, such as CMV, as described in the protocol
  11. Known to both allopurinol and rasburicase

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    REGN7945+Linvoseltamab

    Phase 1 Phase 2

    Drug: REGN7945+Linvoseltamab

  • Experimental
    Linvoseltamab

    Phase 2

    Drug: Linvoseltamab · Drug: REGN7945+Linvoseltamab

Interventions

  • Administered per protocol

    Also known as: REGN5458

  • DrugREGN7945+Linvoseltamab

    Drug page: Linvoseltamab

    Administered per protocol

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs) from the first dose of REGN7945 in combination with linvoseltamab

    Phase 1

    Time frame: Up to 21 days

  2. Incidence of treatment emergent adverse events (TEAEs) during the treatment period with REGN7945 in combination with linvoseltamab

    Phase 1

    Time frame: Up to 5 years

  3. Severity of TEAEs during the treatment period with REGN7945 in combination with linvoseltamab

    Phase 1

    Time frame: Up to 5 years

  4. Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination therapy

    Phase 2

    Time frame: Within 12 weeks of starting cycle 1

  5. VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving linvoseltamab monotherapy

    Phase 2

    Time frame: Within 12 weeks of starting cycle 1

  6. Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination therapy

    Phase 2

    Time frame: Within 12 weeks of starting cycle 1

  7. PR or better as determined by the investigator using the IMWG response criteria in patients receiving linvoseltamab monotherapy

    Phase 2

    Time frame: Within 12 weeks of starting cycle 1

Secondary outcomes

  1. Incidence of TEAEs

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  2. Severity of TEAEs

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  3. Concentrations of REGN7945 in the serum

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  4. Concentrations of linvoseltamab in the serum

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  5. Incidence of anti-drug antibodies (ADA) to REGN7945

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  6. Titer of ADA to REGN7945

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  7. Incidence of ADA to linvoseltamab

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  8. Titer of ADA to linvoseltamab

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  9. Change in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) Global Health Status / Quality of Life (GHS/QoL)

    Phase 1 and Phase 2 The EORTC QLQ-C30 is a 30-item validated questionnaire developed to measure patient-reported quality of life using one global health status/quality of life (GHS/QoL) scale, 5 functioning scales (physical, role, emotional, cognitive, and social) ranging from from 1 = "very poor" to 5 = "excellent" and 9 symptom scales/items (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) among patients with cancer, ranging from 1 = "not at all" to 9 = "very much" higher scores indicate higher symptom burden.

    Time frame: Up to 5 years

  10. Change in EORTC QLQ-C30 Physical Functioning (PF)

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  11. Change in EORTC QLQ-C30 Role Functioning (RF)

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  12. Change in EORTC QLQ-C30 pain

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  13. Change in EORTC QLQ-C30 fatigue

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  14. Time to definitive deterioration in EORTC QLQ-C30 GHS/QoL

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  15. Time to definitive deterioration in EORTC QLQ-C30 PF

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  16. Time to definitive deterioration in EORTC QLQ-C30 RF

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  17. Time to definitive deterioration in EORTC QLQ-C30 pain

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  18. Time to definitive deterioration in EORTC QLQ-C30 fatigue

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  19. Time to first improvement in EORTC QLQ-C30 GHS/QoL

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  20. Time to first improvement in EORTC QLQ-C30 PF

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  21. Time to first improvement in EORTC QLQ-C30 RF

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  22. Time to first improvement in EORTC QLQ-C30 pain

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  23. Time to first improvement in EORTC QLQ-C30 fatigue

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  24. Change in EORTC QLQ-Multiple Myeloma Module (MY20) Disease Symptoms (DS)

    Phase 1 and Phase 2 The EORTC QLQ-MY20 is a self -administered instrument to assess QoL in persons with Multiple Myeloma (MM). This 20-item questionnaire measures the following domains: symptom scales, including disease symptoms (6 items) and symptoms related to side effects of treatment (10 items); function scale and future perspective (3 items); and body image (1 item). A high score represents a high level of symptoms or problems.

    Time frame: Up to 5 years

  25. Change in EORTC QLQ-MY20 Treatment Side Effects (TSE)

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  26. Change in EORTC QLQ-MY20 Body Image (BI)

    Phase 1 and Phase 2

    Time frame: UP to 5 years

  27. Change in EORTC QLQ-MY20 Future Perspective (FP)

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  28. Time to definitive deterioration in EORTC QLQ-MY20 DS

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  29. Time to definitive deterioration in EORTC QLQ-MY20 TSE

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  30. Time to definitive deterioration in EORTC QLQ-MY20 BI

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  31. Time to definitive deterioration in EORTC QLQ-MY20 FP

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  32. Time to first improvement in EORTC QLQ-MY20 DS

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  33. Time to first improvement in EORTC QLQ-MY20 TSE

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  34. Time to first improvement in EORTC QLQ-MY20 BI

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  35. Time to first improvement in EORTC QLQ-MY20 FP

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  36. Change in EuroQoL-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Visual Analogue Score (VAS) (EQ-5D-5L VAS)

    Phase 1 and Phase 2 The EQ-5D-5L is a generic questionnaire that measures Health-Related Quality of Life (HRQoL) across 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) across 5 levels (no problems, slight problems, some problems, severe problems and extreme problems) and a visual analogue scale (VAS).

    Time frame: Up to 5 years

  37. Time to definitive deterioration in EQ-5D-5L VAS

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  38. Time to first improvement in EQ-5D-5L VAS

    Phase 1 and Phase 2

    Time frame: Up to 5 days

  39. Patient-reported overall impact of treatment toxicity measured by Functional Assessment of Cancer Therapy (FACIT)-Item GP5

    Phase 1 and Phase 2 FACIT-Item GP5 will be used to assess the patient-reported impact of treatment toxicity that uses a single item "I am bothered by side effects of treatment" on a 5-point scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much).

    Time frame: Up to 5 years

  40. Objective Response Rate (ORR) as measured by IMWG criteria as determined by the investigator

    Phase 1

    Time frame: Up to 5 years

  41. Complete response (CR) rate as measured by IMWG criteria as determined by the investigator

    Phase 1

    Time frame: Up to 5 years

  42. Duration of response (DOR) by IMWG criteria as determined by the investigator

    Phase 1

    Time frame: Up to 5 years

  43. Progression Free Survival (PFS) as measured by IMWG criteria as determined by the investigator

    Phase 1

    Time frame: Up to 5 years

  44. Achievement of Minimal Residual Disease (MRD) negative status (at 10^5) in participants in CR or better

    Phase 1

    Time frame: Up to 5 years

  45. Overall survival (OS)

    Phase 1

    Time frame: Up to 5 years

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Nov 2033, 107 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 107 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2024
First posted
Nov 1, 2024
StartActual
Dec 11, 2024
Primary completionEst.
Nov 11, 2033
CompletionEst.
Nov 1, 2035
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06669247
Responsible party
Sponsor
First posted
Nov 1, 2024
Start date
Dec 11, 2024
Primary completion
Nov 11, 2033 (estimated)
Completion
Nov 1, 2035 (estimated)
Last update
Aug 5, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linvoseltamab

Start the discussion